trial · primary record
everolimus
Estrogen Receptor Negative
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 27 |
| Primary completion | 2020-03-03 |
| Primary endpoint | Number of Participants Experiencing a Dose Limiting Toxicity (DLT) (Phase I) and the Recommended Phase IB Dose (RP2D) |
| Registry ID | NCT02120469 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:54.273Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02120469
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- EVEROLIMUS · approval
- EVEROLIMUS · approval
- Everolimus · compound